
 
 
 
 
 
 
 
 
 The invention claimed is: 
   
 1. A compound of formula I: 
 
 
 
 
   
   
 
 
 R 6  and R 9  are independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, nitro, Me 3 Sn and halo; 
 where R and R′ are independently selected from optionally substituted C 1-12  alkyl, C 3-20  heterocyclyl and C 5-20  aryl groups; 
 R 7  is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, nitro, Me 3 Sn and halo; 
 R″ is a C 3-12  alkylene group, which chain may be interrupted by one or more heteroatoms selected from O, S, NR N2  (where R N2  is H or C 1-4  alkyl), and/or aromatic rings selected from benzene or pyridine; 
 Y and Y′ are selected from O, S, or NH; 
 R 6′ , R 7′ , R 9′  are selected from the same groups as R 6 , R 7  and R 9  respectively; 
 R 11b  is selected from OH, OR A , where R A  is C 1-4  alkyl; and 
 R L  is a linker for connection to a cell binding agent, which has the formula IIIa: 
 
 
 
 
 
   
   
 
 
 wherein 
 Q is: 
 
 
 
 
 
   
   
 
 
 
 where Q X  is such that Q is an amino-acid residue, a dipeptide residue or a tripeptide residue;
 X is: 
 
 
 
 
 
   
   
 
 
 where a=0 to 5, b=0 to 16, c=0 or 1, d=0 to 5; 
 G L  is a linker for connecting to a Ligand Unit; and 
 either
 (a) R 20  is H, and R 21  is OH or OR A , where R A  is C 1-4  alkyl; or 
 (b) R 20  and R 21  form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or 
 (c) R 20  is H and R 21  is SO z M, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; or 
 (d) R 20  is H and R 21  is H; or 
 (e) R 21  is OH or OR A , where R A  is C 1-4  alkyl and R 20  is selected from:
 (d-i) 
 
 
 
 
 
 
 
   
   
 
 
 
 
 (d-ii) 
 
 
 
 
 
 
 
   
   
 
 
 
 
 (d-iii) 
 
 
 
 
 
 
 
   
   
 
 
 
 
  where R Z  is selected from:
 (z-i) 
 
 
 
 
 
 
 
 
   
   
 
 
 
 
 
 (z-ii) OC(═O)CH 3 ; 
 (z-iii) NO 2 ; 
 (z-iv) OMe; and 
 (z-v) —C(═)—X 1 —NHC(═O)X 2 —NH—R ZC , where —C(═O)—X 1 —NH— and —C(═O)—X 2 —NH— represent natural amino acid residues and R ZC  is selected from Me, OMe, OCH 2 CH 2 OMe. 
 
 
 
 
 
     
 2. The compound according to  claim 1 , wherein both and Y′ are O and R″ is:
 (a) C 3-7  alkylene; or 
 (b) a group of formula: 
 
 
 
 
 
   
   
 
 
 where r is 1 or 2. 
 
 
     
 3. The compound according to  claim 1 , wherein R 9  is H and R 6  is H. 
 
     
 4. The compound according to  claim 1 , wherein R 7  is a C 1-4  alkyloxy group. 
 
     
 5. The compound according to  claim 1 , wherein RU is the same group as R 6 , R 7′  is the same group as R 7 , R 9′  is the same group as R 9  and Y′ is the same group as Y. 
 
     
 6. The compound according to  claim 1 , wherein R 20  and R 21  form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound. 
 
     
 7. The compound according to  claim 1 , which is of formula Ia, Ib or Ic: 
 
 
 
 
   
   
 
 
 where R 1a  is selected from methyl and benzyl; 
 R L  and R 11b  are as defined in  claim 1 . 
 
 
     
 8. The compound according to  claim 1 , wherein R 11b  is OH. 
 
     
 9. The compound according to  claim 1 , wherein Q is a dipeptide residue selected from:
   CO -Phe-Lys- NH , 
   CO -Val-Ala- NH , 
   CO -Val-Lys- NH , 
   CO -Ala-Lys- NH , 
   CO -Val-Cit- NH , 
   CO -Phe-Cit- NH , 
   CO -Leu-Cit- NH , 
   CO -Ile-Cit- NH , 
   CO -Phe-Arg- NH , and 
   CO -Trp-Cit- NH . 
 
 
     
 10. The compound according to  claim 1 , wherein a is 0. 
 
     
 11. The compound according to  claim 1 , wherein b is 0 to 8. 
 
     
 12. The compound according to  claim 1 , wherein d is 2. 
 
     
 13. The compound according to  claim 1 , wherein G L  is selected from: 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 where Ar represents a C 5-6  arylene group, and Hal represents I, Br or Cl. 
 
 
     
 14. The compound according to  claim 13 , wherein G L  is G L1-1 . 
 
     
 15. The compound according to  claim 1 , wherein the compound is of formula Id: 
 
 
 
 
   
   
 
 
 where Q′ is selected from: 
 (a) —CH 2 —; 
 (b) —C 3 H 6 —; and 
 (c) 
 
 
 
 
 
   
   
 
 
 
 
     
 16. A conjugate of formula II:
   L-(D L ) p   (II)
 
 wherein L is a Ligand unit, D L  is a Drug Linker unit of formula I′: 
 
 
 
 
 
   
   
 
 
 wherein R 6 , R 7 , R 9 , R 11b , Y, R″, Y′, R 6′ , R 7 , R 9′ , R 20  and R 21 , are as defined in  claim 1 ; 
 R LL  is a linker for connection to the ligand unit, which has the formula IIIa′: 
 
 
 
 
 
   
   
 
 
 where Q and X are as defined in  claim 1  and G LL  is a linker connected to a Ligand Unit; 
 and 
 wherein p is an integer of from 1 to 20. 
 
 
     
 17. The conjugate according to  claim 16 , wherein is selected from: 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 where Ar represents a C 5-6  arylene group. 
 
 
     
 18. The conjugate according to  claim 17 , wherein G LL  is G LL1-1 . 
 
     
 19. The conjugate according to  claim 16 , wherein D L  is of formula (Id′): 
 
 
 
 
   
   
 
 
 where Q′ is selected from: 
 (a) —CH 2 —; 
 (b) —C 3 H 6 —; and 
 (c) 
 
 
 
 
 
   
   
 
 
 
 
     
 20. The conjugate according to  claim 16 , wherein the Ligand Unit is an antibody or an active fragment thereof which binds to one or more tumor-associated antigens or cell-surface receptors selected from:
 (1) BMPR1B; 
 (2) E16; 
 (3) STEAP1; 
 (4) 0772P; 
 (5) MPF; 
 (6) Napi3b; 
 (7) Sema 5b; 
 (8) PSCA hlg; 
 (9) ETBR; 
 (10) MSG783; 
 (11) STEAP2; 
 (12) TrpM4; 
 (13) CRIPTO; 
 (14) CD21; 
 (15) CD79b; 
 (16) FcRH2; 
 (17) HER2; 
 (18) NCA; 
 (19) MDP; 
 (20) IL20R-alpha; 
 (21) Brevican; 
 (22) EphB2R; 
 (23) ASLG659; 
 (24) PSCA; 
 (25) GEDA; 
 (26) BAFF-R; 
 (27) CD22; 
 (28) CD79a; 
 (29) CXCR5; 
 (30) HLA-DOB; 
 (31) P2X5; 
 (32) CD72; 
 (33) LY64; 
 (34) FcRH1; 
 (35) IRTA2; 
 (36) TENB2; 
 (37) PSMA—FOLH1; 
 (38) SST; 
 (38.1) SSTR2; 
 (38.2) SSTR5; 
 (38.3) SSTR1; 
 (38.4) SSTR3; 
 (38.5) SSTR4; 
 (39) ITGAV; 
 (40) ITGB6; 
 (41) CEACAM5; 
 (42) MET; 
 (43) MUC1; 
 (44) CA9; 
 (45) EGFRvIII; 
 (46) CD33; 
 (47) CD19; 
 (48) IL2RA; 
 (49) AXL; 
 (50) CD30—TNFRS8; 
 (51) BCMA—TNFRSF17; 
 (52) CT Ags—CTA; 
 (53) CD174 (Lewis Y)—FUT3; 
 (54) CLEC14A; 
 (55) GRP78—HSPA5; 
 (56) CD70; 
 (57) Stem Cell specific antigens; 
 (58) ASG-5; 
 (59) ENPP3; 
 (60) PRR4; 
 (61) GCC—GUCY2C; 
 (62) Liv-1—SLC39A6; 
 (63) 5T4; 
 (64) CD56—NCMA1; 
 (65) CanAg; 
 (66) FOLR1; 
 (67) GPNMB; 
 (68) TIM-1—HAVCR1; 
 (69) RG-1/Prostate tumor target Mindin—Mindin/RG-1; 
 (70) B7-H4—VTCN1; 
 (71) PTK7; 
 (72) CD37; 
 (73) CD138—SDC1; 
 (74) CD74; 
 (75) Claudins—CLs; 
 (76) EGFR; 
 (77) Her3; 
 (78) RON—MST1R; 
 (79) EPHA2; 
 (80) CD20—MS4A1; 
 (81) Tenascin C—TNC; 
 (82) FAP; 
 (83) DKK-1; 
 (84) CD52; 
 (85) CS1-SLAMF7; 
 (86) Endoglin—ENG; 
 (87) Annexin A1—ANXA1; and 
 (88) V-CAM (CD106)—VCAM1. 
 
 
     
 21. The conjugate according to  claim 16  wherein p is an integer from 1 to 8. 
 
     
 22. A pharmaceutical composition comprising the conjugate of  claim 16 , and a pharmaceutically acceptable diluent, carrier or excipient. 
 
     
 23. A method of treating a mammal having ovarian cancer, comprising administering to the mammal an effective amount of a conjugate according to  claim 16 . 
 
   
 
 
 
 
 
 
 
 
